Physician profile
Anna S Meyer
NPI 1720472699
$9,580.12
in general payments reported to CMS, 2019-2025
25 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $742 · 2021: $618 · 2022: $1,098 · 2023: $2,330 · 2024: $1,890 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,129 · Education: $65.37 · Consulting Fee: $25.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,128.78 |
| Education | $65.37 |
| Consulting Fee | $25.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,279.61 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,496.84 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $914.75 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $585.30 | 2021-2025 | Hyqvia, Takhzyro, Cuvitru |
| Genentech USA, INC. | $520.97 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $477.84 | 2020-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $398.37 | 2021-2025 | Orladeyo |
| Genentech, INC. | $397.90 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $396.32 | 2021-2025 | Dupixent |
| Csl Behring | $268.56 | 2023-2025 | Hizentra, Haegarda, Kcentra |
| Blueprint Medicines Corporation | $264.41 | 2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $179.78 | 2023-2025 | |
| Grifols USA, LLC | $142.38 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Abbvie INC. | $116.06 | 2022-2024 | |
| Pfizer INC. | $110.97 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $93.50 | 2022-2023 | Tezspire |
| Optinose US, INC. | $91.04 | 2022-2025 | |
| Kaleo, INC. | $87.60 | 2023-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $65.37 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $59.30 | 2022 | |
| Leo Pharma INC. | $50.66 | 2024-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.79 | 2022 | |
| Adma Biomanufacturing LLC | $25.20 | 2025 | |
| Cycle Pharmaceuticals INC | $23.03 | 2025 | Sajazir |
| Organon LLC | $7.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.